Abstract 128P
Background
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer-related deaths in the world. Gastric cancer still constitutes a major global health problem in Asian countries; however there is limited data of the clinical outcome of gastric cancer in the Philippines. Thus this study aimed to determine the survival outcome of gastric adenocarcinoma patients in our institution.
Methods
This was a single-center 10-year retrospective study of gastric adenocarcinoma patients in our institution from January 2010 to December 2019. Categorical data were reported as number with percentage and continuous variables were reported as median. Survival outcomes were calculated using Kaplan-Meier method. Cox proportional hazards (PH) model was used to estimate the effect of variables on event-free survival (EFS) and overall survival (OS). P value of < 0.05 was set to indicate a statistically significant difference.
Results
Median age of diagnosis was 57 years old (range 20 to 86 years old). The majority (78%) of patients were younger than 70 years old and majority were males (62.1%). Abdominal pain was the most common presenting symptom. Patients had stage III (25.8%) and stage IV (54.5%) at diagnosis. Liver was the most common site of metastasis. Most gastric lesions were located at the proximal third (cardia and gastroesophageal area), poorly differentiated, diffuse type, Her2 negative, H.pylori negative. Majority of patients had normal body mass index, no comorbidities, and were non-smokers. Median overall event-free survival (EFS) for all patients was 7.1 months (95% CI 4.8 to 9.4) and median overall survival (OS) was 8.7 months (95% CI 6.4 to 11.1). Using multivariable analysis, the predictors for both EFS and OS were stage at diagnosis, Lauren’s histologic classification and smoking status.
Conclusions
Survival outcome of gastric cancer patients in our institution is similar to that in other Asian countries. Advanced stage at diagnosis was largely responsible for low survival. Early screening and patient education are needed to help improve survival outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02
119P - Clinicopathological features and roles of lymph node metastases in gastric cancer: A single-center retrospective study in China
Presenter: yuming zhang
Session: Poster viewing 02
120P - Clinical implication of DNA damage response gene in advanced gastric cancer stage IV and recurrent gastric cancer patients after gastrectomy treated palliative chemotherapy
Presenter: In Gyu Hwang
Session: Poster viewing 02
121P - Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
Presenter: Amrith B P
Session: Poster viewing 02
122P - Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
Presenter: Amrith B P
Session: Poster viewing 02
123P - Sarcomatoid carcinoma of gall bladder: A series of 14 cases from a single tertiary-care oncology centre
Presenter: Subhash Yadav
Session: Poster viewing 02
124P - Clinical profile and treatment outcomes of hepatocellular carcinoma from a tertiary care hospital in South India: A retrospective study
Presenter: Gayathri Nair
Session: Poster viewing 02
125P - A parametric network meta-analysis of PD-1 inhibitors in second-line treatment for advanced esophageal squamous cell carcinoma
Presenter: Shubhram Pandey
Session: Poster viewing 02
126P - Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Presenter: Keitaro Shimozaki
Session: Poster viewing 02
127P - LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Presenter: Jirapat Wonglhow
Session: Poster viewing 02